-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Biotech company Mydecine Innovations Group (OTC:MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company's drug product.
Mydecine focuses on developing first and second-generation novel therapeutics for the treatment of mental health disorders, mostly though not exclusively PTSD, depression, anxiety and addiction. The company seeks to collaborate with world authorities to responsibly fast-track the development of new medicines to provide patients with safe & effective treatment options.
The trial, conducted by Mydecine and funded by an approximate $4 million grant from the National Institutes of Health, constitutes a milestone in psychedelic studies. According to the company, this is the first time in 50 years the U.S. government has given financial aid to a study for the evaluation of a psychedelic compound for therapeutic use.
"The FDA clearance is encouraging as we prepare to submit the IND for our Industry Sponsored Phase 2b trial using the same drug products," said Mydecine CEO Josh Bartch.
The randomized clinical study seeks to determine if psilocybin increases smoking abstinence compared to a placebo. An integration model will be used; both groups will be paired with cognitive-behavioral therapy (CBT). It is led by PI Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University. Johnson has more than 16 years of experience in researching and publishing on psychedelics.
The grant-funded research and Mydecine's Phase 2b study expand on a 2014 trial led by Dr. Johnson on the efficacy of psilocybin in combination with CBT as a treatment for tobacco addiction. The results: six months after the trial's start, 80% of individuals were biologically proven to be smoking abstinent.
The list of participating investigators includes Michael P. Bogenschutz, M.D., director of the NYU Langone Center for Psychedelic Medicine and professor, Department of Psychiatry at NYU Grossman School of Medicine, and Peter Hendricks, Ph.D., professor in the Department of Health Behavior at the University of Alabama School of Public Health.
Photo Courtesy of Sabine R on Unsplash.
Biotech company Mydecine Innovations Group (OTC:MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company's drug product.
生物技術公司Mydecine創新集團(場外交易代碼:MYCOF)他們的新專利獲得了FDA的批准MYCO-001。這是該公司藥品的首次清關。
Mydecine focuses on developing first and second-generation novel therapeutics for the treatment of mental health disorders, mostly though not exclusively PTSD, depression, anxiety and addiction. The company seeks to collaborate with world authorities to responsibly fast-track the development of new medicines to provide patients with safe & effective treatment options.
Mydecine專注於開發第一代和第二代新療法,用於治療精神健康障礙,主要但不限於創傷後應激障礙、抑鬱、焦慮和成癮。該公司尋求與世界權威機構合作,負責任地加快新藥的開發,為患者提供安全有效的治療選擇。
The trial, conducted by Mydecine and funded by an approximate $4 million grant from the National Institutes of Health, constitutes a milestone in psychedelic studies. According to the company, this is the first time in 50 years the U.S. government has given financial aid to a study for the evaluation of a psychedelic compound for therapeutic use.
這項試驗由Mydecine和由美國國立衞生研究院提供的大約400萬美元的贈款資助,構成了迷幻研究的一個里程碑。據該公司稱,這是50年來美國政府首次為一項研究提供財政援助,該研究旨在評估一種用於治療的迷幻化合物。
"The FDA clearance is encouraging as we prepare to submit the IND for our Industry Sponsored Phase 2b trial using the same drug products," said Mydecine CEO Josh Bartch.
FDA的批准令人鼓舞,因為我們準備提交使用相同藥物產品的行業贊助的2b期試驗的INDMydecine首席執行官喬希·巴奇。
The randomized clinical study seeks to determine if psilocybin increases smoking abstinence compared to a placebo. An integration model will be used; both groups will be paired with cognitive-behavioral therapy (CBT). It is led by PI Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University. Johnson has more than 16 years of experience in researching and publishing on psychedelics.
這項隨機的臨牀研究試圖確定如果裸蓋菇素與安慰劑相比能增加戒煙率。一個整合模式將使用;兩個組都將與認知行為療法(CBT)。它是由Pi領導的馬修·約翰遜博士.,精神病學及行為科學教授約翰霍普金斯大學。約翰遜在迷幻藥的研究和出版方面有超過16年的經驗。
The grant-funded research and Mydecine's Phase 2b study expand on a 2014 trial led by Dr. Johnson on the efficacy of psilocybin in combination with CBT as a treatment for tobacco addiction. The results: six months after the trial's start, 80% of individuals were biologically proven to be smoking abstinent.
這項由贈款資助的研究和Mydecine的2b期研究擴大了2014 由約翰遜博士領導的關於阿司匹林療效的試驗裸蓋菇素聯合CBT治療煙草成癮。結果:試驗開始六個月後,80%的人被生物學證明是戒煙的.
The list of participating investigators includes Michael P. Bogenschutz, M.D., director of the NYU Langone Center for Psychedelic Medicine and professor, Department of Psychiatry at NYU Grossman School of Medicine, and Peter Hendricks, Ph.D., professor in the Department of Health Behavior at the University of Alabama School of Public Health.
參與調查的人員名單包括Michael P.Bogenschutz,醫學博士,董事的紐約大學朗格尼中心紐約大學格羅斯曼醫學院精神病學系教授兼迷幻藥,以及彼得·亨德里克斯博士。,該大學健康行為系教授阿拉巴馬大學公共衞生學院。
Photo Courtesy of Sabine R on Unsplash.
照片由薩賓·R在Unspash上提供。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧